Page 4 - Tapestri Platform News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Mission Bio, the life sciences company delivering single-cell resolution multi-omics tools to accelerate discoveries and improve time-to-market for new therapeutics, announced today a new peer-reviewed study published using the Tapestri Platform's single-cell multi-omics solution to accurately distinguish leukemic cells from clonal hematopoiesis of indeterminate potential (CHIP) in relapsed AML patients. These findings highlight the potential of single-cell proteogenomics to vastly improve disease monitoring post-treatment, specifically for measurable residual disease (MRD) in hematologic...

Mission Bio Launches Pharma Assay Development Services to Speed Access to New Technologies New service reduces project time from months to weeks for biopharma customers News provided by Share this article SOUTH SAN FRANCISCO, Calif., April 20, 2021 /PRNewswire/ -- Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced the launch of its Pharma Assay Development (PAD) services to accelerate biomarker discovery and cell and gene therapy development pipelines for biopharma customers. The PAD Team will provide customers with early access to services...

Press release content from PR Newswire. The AP news staff was not involved in its creation. Mission Bio Announces Yan Zhang as New CEO April 8, 2021 GMT SAN FRANCISCO, April 8, 2021 /PRNewswire/ -- Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced the appointment of Yan Zhang to the role of CEO. Zhang joins Mission Bio after 10 years at Thermo Fisher Scientific, where she drove above-market growth for multiple business lines, including leading the commercial organization in China for Genetic Sciences and Clinical Next-Generation Sequencing d...

New Study Precisely Characterizes Tumor Heterogeneity in AML Patients Using Mission Bio's Tapestri Platform Validates multi-omics techniques for measuring therapeutic responses to AML, holding promise for future blood cancer treatments News provided by Share this article   Mission Bio, the life sciences company delivering single-cell resolution multi-omics tools to accelerate discoveries and improve time-to-market for new therapeutics, today announced a new study published in Nature Communications using its Tapestri Platform to perform high-throughput single-cell proteogenomic profiling to ...